Displaying 201 - 220 of 853
| Active Ingredient | EPHEDRINE HYDROCHLORIDE |
| Therapeutic Class | ALPHA & BETA ADRENERGIC AGONIST |
| Indications | Reversal of hypotension from spinal or epidural anaesthesia |
| Caution |
Anginal pain; anxiety; arrhythmias; flushing; headache; hypersalivation. |
| Dose Range | 3-6 mg every 3-4 minutes (max. p er dose 9 mg), adjusted according to response, injection solution to contain ephedrine hydrochloride 3 mg/ml; maximum 30 mg p er course. |
| Drug Interactions | |
| Pregnancy | Increased fetal heart rate has been reported. Use with caution during pregnancy. |
| Breast Feeding |
| Active Ingredient | NORADRENALINE |
| Therapeutic Class | ALPHA & BETA ADRENERGIC AGONIST |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PSEUDOEPHEDRINE |
| Therapeutic Class | ALPHA & BETA ADRENERGIC AGONIST |
| Indications | Symptomatic relief of nasal congestion. |
| Caution | Tachycardia, anxiety, restlessness, and insomnia. |
| Dose Range | Adults and children over 12 years: 60mg every 4-6 hours to a maximum of 4 doses in 24 hours; patients with renal dysfunction should have dose adjustments. Pediatric: 6-12 years: 30mg 3-4 times daily. |
| Drug Interactions | |
| Pregnancy | Pseudoephedrine should be avoided during pregnancy because of the severity of th More ... |
| Breast Feeding | May suppress lactation; avoid if lactation is not well established or if milk pr More ... |
| Active Ingredient | PIRIBEDIL |
| Therapeutic Class | SYMPATHOLYTIC (ADRENERGIC BLOCKING) AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TAMSULOSIN MR |
| Therapeutic Class | SELECTIVE ALPHA 1 ADRENERGIC BLOCKING AGENTS |
| Indications | Benign prostatic hyperlasia. |
| Caution | Abnormal ejaculation, dizziness, arthalgia, headache, nausea, diarrhoea, rhinitis and slight reductions in hemoglobin have been reported. Food may decrease absorption of tamsulosin. Alterations in blo More ... |
| Dose Range | The recommended oral dose for the treatment of benign prostatic hyperplasia is 0.4mg once daily,to be taken ½ hour after same meal daily. See BDS supply protocols pg. 11. |
| Drug Interactions | |
| Pregnancy | Use of tamsulosin is not approved for women. |
| Breast Feeding | Use of tamsulosin is not approved for women. |
| Active Ingredient | CYCLOBENZAPRINE |
| Therapeutic Class | CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS |
| Indications | Acute muscle spasm of local origin. |
| Caution | Drowsiness, dizziness, insomnia, anxiety , restlessness, confusion, extrapyramidal symptoms, anticholinergic effects, allergic skin reactions. |
| Dose Range | 10mg three times daily . Maximum dose is 60mg daily . See BDS supply protocols pg. 11. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BACLOFEN |
| Therapeutic Class | GABA DERIVED SKELETAL MUSCLE RELAXANTS |
| Indications | Muscle spasm due to multiple sclerosis, spinal cord lesions, and tardive dyskinesia. |
| Caution | Postural hypotension, sedation, dizziness, drowsiness, depression, hallucinations, G.I. disturbances, blurred vision, allergic reactions, muscular weakness. Avoid alcohol. c.f. prescribing in re More ... |
| Dose Range | Adult and children 10 years and over: ½ - 2 tablets increased gradually until the desired effect is reached 3 times daily .Take with food or milk. Paediatric: 300 mcg/kg daily initially in 4 divided doses, increasing gradually every 3 day s |
| Drug Interactions | |
| Pregnancy | Manufacturer advises use only if potential benefit outweighs risk. |
| Breast Feeding | Small amounts are distributed in breastmilk but are not known to be harmful. |
| Active Ingredient | ATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade (short to intermediate duration) for surgery and intubation. |
| Caution | Flushing; hypotension,Bronchospasm; hypersensitivity; skin reactions; tachycardia. |
| Dose Range | Initially 300–600 micrograms/kg, then (by intravenous injection) 100–200 micrograms/kg as required, alternatively (by intravenous injection) initially 300–600 micrograms/kg, followed by (by intravenous infusion) 300–600 micrograms/kg/hour. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | CISATRACURIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Neuromuscular blockade. |
| Caution | Bradycardia. |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | PANCURONIUM BROMIDE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Usual drug of choice for major surgery and for use with long term ventilation of intensive care patients. |
| Caution |
Caution in hepatic and renal impairment. C.f. prescribing in renal disease p. 34. |
| Dose Range | i.v. 0.05-0.1mg/kg, then 0.01-0.02mg/kg as required. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | SUXAMETHONIUM |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Depolarising muscle relaxant of short duration (about 5 mins). Useful for endotracheal intubation |
| Caution | Tachycardia, apnoea, flushing. |
| Dose Range |
Adults and children: i.v. 0.5-2mg/kg dep ending on degree of relaxation required. c.f. prescribing in liver disease p. 18. |
| Drug Interactions | |
| Pregnancy | Mildly prolonged maternal neuromuscular blockade may occur. |
| Breast Feeding | Discontinue breastfeeding until the mother has recovered from neuromuscular bloc More ... |
| Active Ingredient | TIZANIDINE |
| Therapeutic Class | NEUROMUSCULAR BLOCKING AGENTS |
| Indications | Spasticity associated with multiple sclerosis and cerebrovascular or spinal cord disorders. |
| Caution | Drowsiness, muscle weakness, dry mouth, fatigue, insomnia, G.I. disturbances, dizziness. |
| Dose Range | Adult: 2-4mg three times daily . Maximum dose is 36mg daily. Safety has not been determined in children.See BDS supply protocols pg. 11. |
| Drug Interactions | |
| Pregnancy | Avoid Tizanidine during pregnancy. |
| Breast Feeding | Avoid breastfeeding during Tizanidine therapy. |
| Active Ingredient | ORPHENADRINE |
| Therapeutic Class | SKELETAL MUSCLE RELAXANTS, MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ORPHENADRINE | PARACETAMOL |
| Therapeutic Class | SKELETAL MUSCLE RELAXANTS, MISCELLANEOUS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | BLOOD FORMATION AND COAGULATION |
| Therapeutic Class | BLOOD FORMATION, COAGULATION AND THROMBOSIS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ANTIANAEMIA DRUGS |
| Therapeutic Class | ANTIANEMIA DRUGS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FERROUS FUMARATE |
| Therapeutic Class | IRON PREPARATIONS |
| Indications | Iron deficiency, anaemia. |
| Caution | Black stools, constipation. As for ferrous sulphate/folic acid.Liquid may be taken in water or juice to prevent staining of teeth. Antacids decrease absorption. |
| Dose Range |
Adult: One tablet 3 times daily. Take with food.Pediatric: 3- 6mg/kg daily (maximum 200mg) in 2-3 divided doses. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FERROUS FUMARATE | FOLIC ACID |
| Therapeutic Class | IRON PREPARATIONS |
| Indications | Prophylaxis of iron and folic acid |
| Caution | Do not take within 2 hours of oral tetracy clines. G.I symptoms.Black stools, constipation. As for ferrous sulphate/folic acid.Liquid |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FERROUS SULPHATE |
| Therapeutic Class | IRON PREPARATIONS |
| Indications | Iron deficiency, anaemia. |
| Caution | Do not take within 2 hours of oral tetracy clines. G.I symptoms.Black stools, constipation. As for ferrous sulphate/folic acid.Liquid |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FERROUS SULPHATE | FOLIC ACID |
| Therapeutic Class | IRON PREPARATIONS |
| Indications | Prophylaxis of iron and folic acid deficiencies in pregnancy. |
| Caution | Do not take within 2 hours of oral tetracyclines. G.I. symptoms. |
| Dose Range | Adult: 1-3 tabs daily. Paediatic 6: 12 yrs: 5 mls daily. 2-5 years: 2.5ml daily. Under 2 years:1.25 ml daily. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |